CN1157570A - 化学药物向特定细胞的细胞内载运 - Google Patents

化学药物向特定细胞的细胞内载运 Download PDF

Info

Publication number
CN1157570A
CN1157570A CN95195037A CN95195037A CN1157570A CN 1157570 A CN1157570 A CN 1157570A CN 95195037 A CN95195037 A CN 95195037A CN 95195037 A CN95195037 A CN 95195037A CN 1157570 A CN1157570 A CN 1157570A
Authority
CN
China
Prior art keywords
chemicals
cell
seq
receptor
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN95195037A
Other languages
English (en)
Chinese (zh)
Inventor
R·K·普拉卡施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thera Tech Inc
Original Assignee
Thera Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thera Tech Inc filed Critical Thera Tech Inc
Publication of CN1157570A publication Critical patent/CN1157570A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN95195037A 1994-09-13 1995-09-12 化学药物向特定细胞的细胞内载运 Pending CN1157570A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13
US08/305,770 1994-09-13

Publications (1)

Publication Number Publication Date
CN1157570A true CN1157570A (zh) 1997-08-20

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95195037A Pending CN1157570A (zh) 1994-09-13 1995-09-12 化学药物向特定细胞的细胞内载运

Country Status (13)

Country Link
EP (1) EP0781139A1 (ko)
JP (1) JPH10505835A (ko)
KR (1) KR970705404A (ko)
CN (1) CN1157570A (ko)
AU (1) AU697469B2 (ko)
BR (1) BR9508951A (ko)
CA (1) CA2198361A1 (ko)
CZ (1) CZ74797A3 (ko)
HU (1) HUT77263A (ko)
MX (1) MX9701860A (ko)
PL (1) PL319100A1 (ko)
WO (1) WO1996008263A1 (ko)
ZA (1) ZA957688B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616665B (zh) * 1997-11-19 2010-10-06 乔治敦大学 定向脂质体基因送递

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
JP2003516305A (ja) * 1997-08-05 2003-05-13 ワトソン ファーマシューティカルズ， インコーポレイテッド インターロイキン−２レセプターに標的化された結合体
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616665B (zh) * 1997-11-19 2010-10-06 乔治敦大学 定向脂质体基因送递

Also Published As

Publication number Publication date
CA2198361A1 (en) 1996-03-21
AU3550795A (en) 1996-03-29
MX9701860A (es) 1997-06-28
CZ74797A3 (en) 1997-08-13
JPH10505835A (ja) 1998-06-09
HUT77263A (hu) 1998-03-02
ZA957688B (en) 1996-05-13
WO1996008263A1 (en) 1996-03-21
PL319100A1 (en) 1997-07-21
KR970705404A (ko) 1997-10-09
BR9508951A (pt) 1999-04-06
AU697469B2 (en) 1998-10-08
EP0781139A1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
CN1184235C (zh) 嵌合多肽、其产生方法及应用
JP2996415B2 (ja) 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
EP3352782B1 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
CN1713920A (zh) 被修饰的转铁蛋白融合蛋白
CN1680451A (zh) 包含hpv抗原和应激蛋白或者其表达载体的组合物激发的抗hpv抗原免疫应答
CN1067679A (zh) 重组dna衍生的霍乱毒素亚基类似物
JP2002514892A (ja) 遺伝子治療における合成ウイルス様粒子の使用
CN104245722A (zh) 白细胞介素-10多肽结合物和其用途
CN1134111A (zh) 使用胰岛素样生长因子结合蛋白质的方法
JPS63501799A (ja) Ｃｙｓコドン修飾ＤＮＡ
CN1791679A (zh) 基于CD8α链的具有降低的免疫原性的基因治疗载体
KR20140069222A (ko) 교차 제시 수지상 세포를 표적으로 하는 백시바디
CN104245720A (zh) 白细胞介素-3多肽结合物和其用途
EP2056859B1 (en) Promiscuous pap cd4 t cell epitopes
CN1157570A (zh) 化学药物向特定细胞的细胞内载运
CN1178950C (zh) 司登尼亚蛋白小体-司登尼亚钙蛋白
CN1151760A (zh) 血清对氧磷酶
JP2510846B2 (ja) ＰＥ４０Ａｂを含有するタンパク質抗ガン剤
US5194592A (en) Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
EP0728015B1 (en) Method of producing a set of combinatorial polypeptide antigens
CN1299833A (zh) 抗人血管内皮生长因子单链抗体及其制备方法
MXPA97001860A (en) Intracellular supply of chemical agents, to a specific unit of cel
CN1235910C (zh) 与短肽激素嵌合的靶特异性细胞毒性剂
CN1966529A (zh) 含有促性腺激素释放素和绿脓毒素功能片段的重组毒性剂
JPH02502287A (ja) 改良されたリシン分子およびリシン毒素コンジュゲート

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication